129 related articles for article (PubMed ID: 11751480)
1. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.
Britten CD; Rowinsky EK; Soignet S; Patnaik A; Yao SL; Deutsch P; Lee Y; Lobell RB; Mazina KE; McCreery H; Pezzuli S; Spriggs D
Clin Cancer Res; 2001 Dec; 7(12):3894-903. PubMed ID: 11751480
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
Lobell RB; Liu D; Buser CA; Davide JP; DePuy E; Hamilton K; Koblan KS; Lee Y; Mosser S; Motzel SL; Abbruzzese JL; Fuchs CS; Rowinsky EK; Rubin EH; Sharma S; Deutsch PJ; Mazina KE; Morrison BW; Wildonger L; Yao SL; Kohl NE
Mol Cancer Ther; 2002 Jul; 1(9):747-58. PubMed ID: 12479371
[TBL] [Abstract][Full Text] [Related]
3. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
4. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Patnaik A; Eckhardt SG; Izbicka E; Tolcher AA; Hammond LA; Takimoto CH; Schwartz G; McCreery H; Goetz A; Mori M; Terada K; Gentner L; Rybak ME; Richards H; Zhang S; Rowinsky EK
Clin Cancer Res; 2003 Oct; 9(13):4761-71. PubMed ID: 14581347
[TBL] [Abstract][Full Text] [Related]
5. A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors.
Gore L; Holden SN; Cohen RB; Morrow M; Pierson AS; O'Bryant CL; Persky M; Gustafson D; Mikule C; Zhang S; Palmer PA; Eckhardt SG
Ann Oncol; 2006 Nov; 17(11):1709-17. PubMed ID: 16980604
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors.
Papadimitrakopoulou V; Agelaki S; Tran HT; Kies M; Gagel R; Zinner R; Kim E; Ayers G; Wright J; Khuri F
Clin Cancer Res; 2005 Jun; 11(11):4151-9. PubMed ID: 15930351
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP; Ryan DP; Appleman L; Zhu AX; Puchalski T; He X; Sonnichsen DS; Cooper M; Wright J; Clark JW; Supko JG
Cancer Chemother Pharmacol; 2006 Jul; 58(1):107-16. PubMed ID: 16362299
[TBL] [Abstract][Full Text] [Related]
10. A phase I pharmacokinetic and pharmacodynamic study of the farnesyl transferase inhibitor BMS-214662 in combination with cisplatin in patients with advanced solid tumors.
Mackay HJ; Hoekstra R; Eskens FA; Loos WJ; Crawford D; Voi M; Van Vreckem A; Evans TR; Verweij J
Clin Cancer Res; 2004 Apr; 10(8):2636-44. PubMed ID: 15102665
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Ryan DP; Eder JP; Puchlaski T; Seiden MV; Lynch TJ; Fuchs CS; Amrein PC; Sonnichsen D; Supko JG; Clark JW
Clin Cancer Res; 2004 Apr; 10(7):2222-30. PubMed ID: 15073096
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK
Invest New Drugs; 2012 Feb; 30(1):316-26. PubMed ID: 20839029
[TBL] [Abstract][Full Text] [Related]
16. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Garrison MA; Hammond LA; Geyer CE; Schwartz G; Tolcher AW; Smetzer L; Figueroa JA; Ducharme M; Coyle J; Takimoto CH; De Jager RL; Rowinsky EK
Clin Cancer Res; 2003 Jul; 9(7):2527-37. PubMed ID: 12855627
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
Hammond LA; Eckardt JR; Baker SD; Eckhardt SG; Dugan M; Forral K; Reidenberg P; Statkevich P; Weiss GR; Rinaldi DA; Von Hoff DD; Rowinsky EK
J Clin Oncol; 1999 Aug; 17(8):2604-13. PubMed ID: 10561328
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
Martin NE; Brunner TB; Kiel KD; DeLaney TF; Regine WF; Mohiuddin M; Rosato EF; Haller DG; Stevenson JP; Smith D; Pramanik B; Tepper J; Tanaka WK; Morrison B; Deutsch P; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ; Hahn SM
Clin Cancer Res; 2004 Aug; 10(16):5447-54. PubMed ID: 15328183
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Dy GK; Bruzek LM; Croghan GA; Mandrekar S; Erlichman C; Peethambaram P; Pitot HC; Hanson LJ; Reid JM; Furth A; Cheng S; Martell RE; Kaufmann SH; Adjei AA
Clin Cancer Res; 2005 Mar; 11(5):1877-83. PubMed ID: 15756013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
